Form 4: GoodRx Director Receives Equity Grant
Director Equity Grant
GoodRx Holdings, Inc. director Ronald E. Bruehlman was granted 73,434 deferred stock units as part of his annual compensation.
Summary
- Director Ronald E. Bruehlman acquired 73,434 deferred stock units (DSUs) on June 16, 2026.
- Each DSU represents a contingent right to receive one share of Class A common stock.
- The units vest on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.
- Following this transaction, the director's total beneficial ownership is 207,352 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified; this is a standard director compensation event.
Risks
- Vesting is subject to the director's continued service through the applicable vesting date.
Future Outlook
The deferred stock units are scheduled to settle on the earliest of December 31, 2031, separation from service, a change in control, death, or disability.
Industry Context
StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the healthcare technology sector to ensure long-term alignment with corporate governance and performance goals.
Comparison to Industry Standards
- The grant of deferred stock units is consistent with standard director compensation packages for mid-to-large cap technology and healthcare companies.
- The vesting schedule aligns with typical annual meeting cycles observed in public companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of deferred stock units under the company's Deferred Compensation Plan for Directors. | 06/16/2026 | Standard alignment of director incentives. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity grant.
Next Steps
- Vesting of units on the earlier of June 16, 2027, or the 2027 Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 06/16/2026 | Date of the equity grant transaction. |
| 06/17/2026 | Date of filing. |
Keywords
GoodRx, GDRX, Director Compensation, Equity Grant, Insider Ownership, Deferred Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.